Article

Keytruda Granted Priority Review in Cervical Cancer

Author(s):

Merck filed the supplemental biologics license application based on results from the phase II KEYNOTE-158 trial.

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

The agency has set a PDUFA date of June 28, 2018. Merck, the developer of pembrolizumab, reported in a press release that this is the first time the FDA has given a priority review to an anti—PD-1 therapy in this disease.

“Advanced cervical cancer is an illness with a poor prognosis and a high unmet medical need. We look forward to working with the FDA on the review of this application to help bring Keytruda to previously-treated patients with advanced cervical cancer,” Roger Dansey, MD, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories, said in a statement.

For more information, please visit OncLive.com.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
5 experts in this video